Brian Price, Ph.D. is a seasoned executive with a successful track record of business and product development in both therapeutic and vaccine technology. In addition to his leadership of adopTracell, Dr. Price also serves as Chief Technology Officer for Armatus Bio. Previously, Dr. Price was Principal Consultant at Price Biologics Consulting, LLC, assisting in the development of scalable and efficient Chemistry Manufacturing and Controls (CMC) processes for gene therapy products, and supported the development of an AAV-based COVID vaccine as COO of Albamunity, Inc. He served as VP of Pharmaceutical Development at Myonexus Therapeutics until its acquisition by Sarepta in 2019. Dr. Price also served as COO at Blue Water Vaccines, and previously held a range of leadership roles over the course of a 15-year tenure at Battelle Memorial Institute, including acting lead for business development in the health business unit.
Dr. Price earned his B.S. and Ph.D. in Microbiology from The Ohio State University.
Dr. Shahnawaz Imam is an expert in endocrine autoimmune disease, having focused for the last 10 years together with Dr. Jaume on Type 1 Diabetes (T1D), thyroid autoimmunity and thyroid cancer, exploring the role of the microenvironment in onset and progression of autoimmune diseases like T1D and thyroid cancer. Dr. Imam is working specifically to address antigen-specific and non-specific immunotherapies and immune modulation therapies for treating autoimmune diseases. Dr. Imam’s long-term goal is to develop, implement, and disseminate interventions to reduce the burden of autoimmune diseases like T1D.
After completing a doctorate in veterinary medicine at the Indian Veterinary Research Institute (IVRI), one of the finest institutes of veterinary research in South-West Asia in 2003, Dr. Shanawaz Imam pursued a Research Fellowship for a doctorate at the prestigious Indian Council of Agricultural Research (ICAR). Dr. Imam subsequently moved to the United States for postdoctoral training in the Laboratory of Dr. Ginther first, and then joined Dr. Jaume’s group in the Department of Medicine, Division of Endocrinology, at the University of Wisconsin-Madison, School of Medicine and Life Sciences. In 2015, the group moved to the Division of Endocrinology-Diabetes and Metabolism, Department of Medicine, College of Medicine and Life Sciences, University of Toledo, Ohio.
Dr. Juan Carlos Jaume, MD founded adopTracell in 2020 to advance our technology from extensive basic research into clinical development. Dr. Jaume was most recently the Chief of Endocrinology and Director of the Center for Diabetes and Endocrine Research (CeDER) at the University of Toledo College of Medicine (formerly known as the Medical College of Ohio). He previously served as head of the Thyroid Multidisciplinary Clinic and then Chief of Endocrinology at the Madison Veterans Administration Medical Center at the University of Wisconsin-Madison. Previously he was on the faculty of the University of California, San Francisco.
Dr. Jaume received post-doctoral training at Albert Einstein College of Medicine (Internal Medicine Residency) and at the University of California, San Francisco (1. Endocrinology, Diabetes and Metabolism Fellowship; 2. Molecular Medicine Fellowship) under the mentorship of pioneers in the diabetes field Dr. Steinunn Baekkeskov and in thyroid diseases Dr. Basil Rapoport.